ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

1200mg of tqb2928 injection

A development code. Also written as “1200mg of TQB2928 injection+Anlotinib”, “1800mg of TQB2928 injection+Anlotinib” and “TQB2928 injection + Almonertinib Mesilate Tablets”.

In Sino Biopharmaceutical’s pipeline, CD47单抗. Its studies are mostly in Osteosarcoma · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.

Furthest: phase 1, since May 27, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical21 open or runningphase 1since May 27, 2024May 27, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2928, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2024First study: phase 1 study in OsteosarcomaFirst studyNCT06438783 · 20 enrolled · China
  2. Sep 1, 2024Phase 1 study in Advanced Non-small Cell Lung CancerNCT06585059 · 20 planned · China

TargetBeta

“CD47单抗”the company's pipeline, read by Claude · source

Other programs on CD47

ProgramCompanyFurthest phaseStudies
ligufalimabruleAkesophase 311
evorpaceptrulealx-oncology-incphase 39
Anti-PD-1/CD47 Fusion Protein HX009rulehangzhou-hanx-biopharmaceuticals-ltdphase 25
CD47 Antagonist AUR103 CalciumruleDr. Reddy's Laboratoriesphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06585059Advanced Non-small Cell Lung Cancer · China1Not yet recruitingDec 202520
NCT06438783Osteosarcoma · China1TerminatedJun 18, 202520

How it is read

Names in the registry

  • “1200mg of TQB2928 injection+Anlotinib”, 1 entry
  • “1800mg of TQB2928 injection+Anlotinib”, 1 entry
  • “TQB2928 injection + Almonertinib Mesilate Tablets”, 1 entry

Codes read as this program: TQB2928.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.